مجله علمی پژوهشی سازمان نظام پزشکی
Volume 36, Issue 2 (2019)                   jmciri 2019, 36(2): 67-73 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Haj Hossein Talasaz A, Ghaffari S. A Comprehensive Review on Medication Used for Warfarin Reversal. jmciri 2019; 36 (2) :67-73
URL: http://jmciri.ir/article-1-2835-en.html
School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Abstract:   (3378 Views)
Warfarin sodium as an anticoagulant, is widely used for the prevention and treatment of venous and arterial thrombosis. As a vitamin K antagonist, warfarin effectively decreases the hepatic production of clotting factors II, VII, IX, and X, along with proteins C and S. While anticoagulants such as warfarin have well-established indications, they are also associated with few side effects such as haemorrhage.
Many patients receiving vitamin K antagonists have an International Normalized Ratio (INR) higher than the target of 2.0 to 3.0 for over 50% of the time, which is followed with increasing risk of bleeding. In this situation the clinical need for emergency reversal of anticoagulation is necessary. There are a number of potential treatment options for anticoagulant reversal, including administration of vitamin K (oral or intravenous), human plasma products [for example, Fresh Frozen Plasma (FFP)], prothrombin complex concentrates (PCCs); concentrates that contain coagu-lation factors II, VII, IX and X), or single coagulation factors such as activated re-combinant factor VII (rFVIIa).
The aim of this paper was to conduct a review of the medical literature and summarize the advantages and risks of the available treatment options for reversing warfarin anticoagulation in patients receiving warfarin.

 
Full-Text [PDF 353 kb]   (1448 Downloads)    
Type of Study: Research | Subject: General

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.